BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...

Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Sector ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Avidity Biosciences (RNA – Research ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), ...

Friday - Cantor Fitzgerald reaffirmed its Overweight rating and $96.00 price target for Avidity Biosciences (NASDAQ:RNA) stock, representing significant upside from the current ...

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an impressive ...

ConocoPhillips (NYSE:COP – Get Free Report) has earned a consensus rating of “Buy” from the nineteen ratings firms that are ...

Colossal Biosciences, a Texas-based company, genetically engineered a woolly mouse, marking an achievement toward its goal of resurrecting extinct species like the woolly mammoth. The woolly mouse ...

The global Cell Penetrating Peptide Market is poised for exceptional growth, as it is projected to surge from US$ 2.16 billion in 2024 to an impressive US$ 8.12 billion by 2033, e ...

Feetures, America's #1 running sock, is dedicated to supporting athletes of all ages and promoting the importance of being ...